CoreCap Advisors LLC Invests $53,000 in AstraZeneca PLC (NASDAQ:AZN)

CoreCap Advisors LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 778 shares of the company’s stock, valued at approximately $53,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AZN. Parkside Financial Bank & Trust raised its holdings in AstraZeneca by 4,875.0% during the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock worth $26,000 after purchasing an additional 390 shares in the last quarter. Fairfield Bush & CO. bought a new stake in AstraZeneca during the first quarter worth approximately $28,000. Accurate Wealth Management LLC bought a new stake in AstraZeneca during the fourth quarter worth approximately $30,000. Red Tortoise LLC bought a new stake in AstraZeneca during the fourth quarter worth approximately $30,000. Finally, Financial Management Professionals Inc. raised its holdings in AstraZeneca by 68.6% during the fourth quarter. Financial Management Professionals Inc. now owns 467 shares of the company’s stock worth $32,000 after purchasing an additional 190 shares in the last quarter. 16.42% of the stock is currently owned by institutional investors and hedge funds.

Get AstraZeneca alerts:

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $73.08 on Thursday. The company’s fifty day moving average is $73.99 and its two-hundred day moving average is $69.10. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.75. AstraZeneca PLC has a 12-month low of $52.65 and a 12-month high of $76.56. The company has a market cap of $226.53 billion, a P/E ratio of 48.08, a price-to-earnings-growth ratio of 1.43 and a beta of 0.52.

Wall Street Analyst Weigh In

AZN has been the topic of several research reports. Argus dropped their price target on AstraZeneca from $85.00 to $80.00 in a report on Friday, May 26th. StockNews.com initiated coverage on AstraZeneca in a report on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Finally, Morgan Stanley raised AstraZeneca from an “equal weight” rating to an “overweight” rating in a report on Tuesday, April 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of $103.00.

AstraZeneca Profile

(Get Rating)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Featured Articles

• Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
• A.I. ETF Sold Out Of Monster Energy, Three Ways To Look At It
• Don’t Worry; Sportsman’s Warehouse Will Get Cheaper 
• Trinseo’s Dip, Has Something Changed Or Is It Just A Down Cycle
• The Most Upgraded Stocks From The Q1 Earnings Season
• What U-Haul Earnings Are Showing, Heading Up?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.